ArticleEMBO reports2026
Differential isoform-specific control of KCC2 function in developing and mature cortical neurons.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The K-Cl cotransporter KCC2 is essential for fast synaptic inhibition in the mature brain. It is encoded by a single gene and expressed as two isoforms: KCC2a and KCC2b, which differ in their N-terminal domains. While KCC2b is predominant, the function of the weakly expressed KCC2a isoform remains unclear. Here, we reveal that KCC2a is a potent, bidirectional regulator of KCC2b membrane stability and function in cortical neurons. In immature neurons, where WNK-SPAK kinase activity is high, KCC2a promotes SPAK-dependent phosphorylation of KCC2b at Thr1007, which likely contributes to hindering its membrane expression and function. Conversely, in mature neurons with low basal WNK-SPAK activity, KCC2a promotes KCC2b expression, clustering, and function. At this stage, although accounting for less than 5% of total KCC2 mRNA, KCC2a is enriched in dendrites and within KCC2 clusters, where it prevents clathrin-mediated KCC2b endocytosis, as well as polyubiquitination and proteasomal degradation. Thus, KCC2a acts as a developmental switch that first inhibits KCC2b during early development and then ensures its membrane stability to support effective synaptic inhibition in the adult brain.
Identifiers
42701150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.